
Pharmaceutics Jabil Strengthens Pharmaceutical Solutions with Acquisition of Pharmaceutics International
Pharmaceutics Jabil a global leader in engineering, manufacturing, and supply chain solutions, has officially completed its acquisition of Pharmaceutics International a contract development and manufacturing organization (CDMO) specializing in early-stage, clinical, and commercial-volume aseptic filling, lyophilization, and oral solid dose manufacturing. The acquisition, finalized on February 3, 2025, marks a significant milestone in Jabil’s continued expansion into the pharmaceutical sector.

Meeting the Growing Needs of the Pharmaceutical Industry
As the pace of healthcare innovation accelerates, pharmaceutical companies require partners who can help them scale rapidly while maintaining the highest standards of quality and safety. With the integration of Pii’s advanced capabilities, Jabil strengthens its role as a comprehensive solutions provider in the pharmaceutical industry.
Mike Mahaz, SVP, Global Business Units, Healthcare, at Jabil, expressed enthusiasm about the acquisition:
“Pharmaceutics Jabil and Pii’s combined capabilities will provide end-to-end support for pharmaceutical customers, offering one safe, trusted pair of hands to simplify their entire supply chain. This acquisition enhances our ability to support customers in developing and commercializing innovative drug delivery solutions.”
Pharmaceutics Jabil has already established itself as a leader in parenteral drug delivery, particularly in support of high-growth pharmaceutical markets such as glucagon-like peptide-1 receptor agonists (GLP-1s). The addition of Pii’s expertise in aseptic filling, lyophilization, and oral solid dose manufacturing significantly enhances Jabil’s existing Pharmaceutical Solutions offering, which includes auto-injectors, pen injectors, inhalers, and on-body pumps.
Expanding Capabilities and Enhancing Customer Offerings
By acquiring Pii, Pharmaceutics Jabil gains access to a wealth of scientific knowledge and product expertise. Pii’s established capabilities in pharmaceutical formulation, development, and manufacturing services allow Jabil to meet the evolving clinical and commercial drug manufacturing demands of its healthcare customers.
James O’Gorman, Vice President, Pharmaceutical Solutions at Jabil, highlighted the strategic importance of the acquisition:
“Pharmaceutics Jabil is very pleased to announce this acquisition. With our shared commitment to creating the best solutions possible for patients around the world, we believe the addition of Pii’s capabilities, supported by over 300 team members, is a perfect fit for Jabil and our customers.”
The integration of Pii’s specialized services bolsters Jabil’s customer offerings and supports its expansion into the CDMO market. With this move, Jabil aims to provide seamless pharmaceutical solutions, from drug formulation to final delivery.
Pii’s State-of-the-Art Facilities and Expertise
Founded in 1994, Pii has grown into a leading CDMO with a substantial operational footprint spanning over 360,000 square feet across four sites located on a single campus in Hunt Valley, Maryland. The company’s Good Manufacturing Practice (GMP) facilities house more than 70 manufacturing rooms, enabling a diverse range of pharmaceutical production activities, including:
- Containment suites for handling high-potency compounds and hormones.
- Dedicated manufacturing suites for oral products, including soft gels.
- Aseptic manufacturing facilities for injectable drugs, including vials, syringes, and cartridges.
- A formulation development center focused on advancing drug product innovation.
- Analytical and microbiology laboratories for quality control and regulatory compliance.
Pii’s cutting-edge facilities and expertise complement Pharmaceutics Jabil’s existing healthcare solutions, creating a comprehensive portfolio that enhances Jabil’s ability to support pharmaceutical customers throughout the drug development lifecycle.
Leveraging Jabil’s Global Infrastructure for Enhanced Growth
By joining Jabil, Pii benefits from access to an expanded global infrastructure, cutting-edge automation, and enhanced supply chain efficiencies. This integration is expected to drive innovation and responsiveness, enabling Jabil to provide even more value to its pharmaceutical partners.
John Fowler, President and CEO of Pii, emphasized the positive impact of the acquisition:
“This acquisition marks an exciting new chapter for Pii. We look forward to leveraging Jabil’s extensive expertise to accelerate our mission of delivering best-in-class drug development and manufacturing solutions to our customers and ultimately the patients we serve.”
With Jabil’s resources and capabilities, Pii is well-positioned to continue its legacy of excellence while expanding its impact within the pharmaceutical industry.
Industry Recognition and Future Prospects
The acquisition has garnered attention from industry stakeholders, recognizing the strategic importance of the deal in shaping the future of pharmaceutical manufacturing and supply chain management. The integration of Jabil’s advanced automation and global reach with Pii’s specialized pharmaceutical expertise is expected to set new industry standards for efficiency, quality, and innovation.
James Gale, Chairman of Pii and Managing Director of Signet Healthcare Partners, expressed confidence in Jabil’s ability to drive future success:
“On behalf of our board and fellow shareholders at Athyrium Capital Management, Hildred Capital, and Pharmascience Inc., I want to thank our management and staff for their splendid work in building the company over the past several years. Jabil is the perfect owner to continue the momentum of the business. With their resources and capabilities, we believe our customers and employees will be well served going forward.”
A Stronger Future for Jabil’s Pharmaceutical Solutions
The acquisition of Pii is part of Jabil’s broader strategy to expand its capabilities in the healthcare sector, particularly in pharmaceutical manufacturing and drug delivery solutions. By combining Jabil’s engineering and manufacturing expertise with Pii’s pharmaceutical development and production capabilities, the company is well-positioned to support pharmaceutical companies in bringing innovative treatments to market more efficiently and effectively.
This acquisition reinforces Jabil’s commitment to advancing pharmaceutical manufacturing and drug delivery solutions, ensuring that healthcare customers have access to reliable, high-quality production capabilities.
As Jabil integrates Pii’s operations, customers can expect a seamless transition, enhanced service offerings, and a continued focus on innovation and excellence in pharmaceutical manufacturing.